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Recent studies have demonstrated that cardiac and skel- 
etal myocytes share the ability to take up and stably express 
plasmid DNA injected directly into myocardium or skeletal 
muscle in vivo. Although this is a relatively inefficient process, 
with less than 1% of the myocytes expressing the injected 
recombinant DNA, expression in these cells is stable for pe- 
riods of at least 6 months. The majority of the injected DNA 
is maintained in myocytes as an episome and apparently 
does not undergo DNA replication. The direct DNA injection 
approach has been used to map cardiac-specific transcrip- 
tional regulatory elements in cellular promoter/enhancers. 
Expression of recombinant proteins in the heart following 
direct DNA injection also holds promise for the treatment of 
a variety of acquired and inherited cardiovascular diseases. 
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A comprehensive analysis of the molecular mecha- 
nisms regulating cardiac gene expression and devel- 
opment has been hindered significantly by our inability 
to grow and manipulate cardiac myocytes in vitro. 
Thus, for example, relatively little is currently under- 
stood about the transcriptional mechanisms regulating 
cardiac muscle development. Similarly, it has not been 
possible to develop therapeutic strategies for cardio- 
vascular diseases based upon stably manipulating car- 
diac gene expression in vitro or in vivo. Recent studies 
have demonstrated that skeletal and cardiac myocytes 
share the unique ability to take up and stably express 
plasmid DNA following direct injection into skeletal 
or cardiac muscle in vivo (l-5). These findings have 
raised the possibility of using direct DNA injection both 
as a tool for studying transcriptional regulation in car- 
diac myocytes in vivo and as a method for programming 
the expression of therapeutic recombinant proteins in 
the heart. In this article, we provide a detailed descrip- 
tion of the methods used for direct DNA injection into 
myocardium and discuss the uses of this technique for 
studying transcriptional regulation in cardiac muscle 
as well as for somatic gene therapy in the heart. We 
have demonstrated that direct DNA injection can be 
used to express a variety of reporter genes in rodent 
myocardial cells in vivo for periods of as long as 6 
months. In addition, we have used direct DNA injec- 
tions into rat myocardium to identify and characterize 
a novel cardiac-specific promoter/enhancer in the slow/ 
cardiac troponin C (cTnC) gene. We discuss the po- 
tential role of intracardiac DNA injection as an ap- 
proach to somatic gene therapy in the heart. 
MATERIALS AND REAGENTS 
Animals 
Sprague-Dawley rats, ages 4-6 weeks: Charles River.’ 
Solutions for DNA Preparation 
3 M sodium acetate,‘pH 5.2. 
100% ethanol. 
70% ethanol in water. 
10 mM NaHZP04, pH 7.4, in 0.88% sodium chloride 
(filter sterilized). 
CsCl: Optical grade, Ultrapure BRL.’ 
Water-saturated l-butanol. ’ 
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Dialysis tubing, $-in. diameter: BRL. 
Anesthetic Agents 
Avertin (2,2,2-tribromoethanol and tert-amyl alco- 
hol), 5% vol/vol in Dulbecco’s PBS (filter sterilized). 
Avertin should be prepared fresh on the day of surgery: 
Aldrich. 
Ketamine: Aveco. 
Pentobarbital: Anthony Products. 
Surgical Equipment 
Small-animal ventilator: Harvard Model 683. 
Veterinary laryngoscope with small base and halogen 
lamp: Welch Allyn. 
Miller blade size 0 (pediatric): Welch Allyn. 
Angiocatheter or long percutaneous catheter, 18- or 
20-gauge size. 
Animal clippers: Oster. 
70% ethanol. 
Scalpel; coarse dissecting scissors; iris scissors, 4 in., 
curved, Castroviejo cornea1 scissors, 3.75 in. with blunt 
points; Hartmann mosquito forceps, 3.5 in., curved; 
Halsted mosquito forceps, 5 in., straight and curved; 
cross-action retractor, 4 in., with blunt prongs; Mayo- 
Hegar needle holder, 5 in.; Autoclip wound clip applier 
with g-mm wound clips, Roboz or Milltex. 
30-gauge X &-in. needle. 
21 gauge X l-in. needle. 
l-ml Tuberculin syringe. 
20-gauge angiocatheter. 
4-O silk suture with conventional cutting (PC-5) 
needle. 
4-O prolene suture with conventional cutting (PC- 
5) needle. 
4-O vicryl suture with conventional cutting (PC-5) 
needle. 
Reagents for /3-Galactosidase (P-Gal), 
Chloramphenicol Acetyltransferase (CAT), 
and Luciferase Assays 
P-Gal Assay 
Glutaraldehyde, 1.25% (vol/vol) in Dulbecco’s PBS: 
BRL. Ferro/ferricyanide solution: 0.1 M potassium 
ferricyanide, 0.1 M potassium ferrocyanide in distilled 
water. Store in the dark at room temperature. 
X-Gal stock solution: 20 mg/ml X-Gal (5-bromo-4- 
chloro-3-indolyl-P-galactoside): BRL or BMB in 100% 
N,N-dimethyl formamide. Store in the dark at -20°C. 
Staining solution: 50 mM Tris-HCl (pH 7.5), ferro/ 
ferricyanide solution (5%), 15 mM NaCl, 1 mM MgClz, 
0.5 mg/ml X-Gal reagent. 
Dulbecco’s PBS, calcium and magnesium free. 
CAT Assay 
Protein calorimetric quantitation kit: Bio-Rad. 
14C-labeled chloramphenicol (D-threo-[dichloroace- 
tyl-l-14C]chloramphenicol), 50-60 mCi/mmol: Amer- 
sham. 
2 M Tris-HCl, pH 7.4. 
4 mM acetyl-CoA: Pharmacia. 
Ethyl acetate. 
Thin-layer chromatography plates: Baker silica 
gel lB-F. 
X-ray film. 
95% chloroform/5% methanol solution. 
Ice-cold Dulbecco’s PBS. 
Luciferase Assay 
Luciferin: Analytical luminescence. 
Luciferase: Analytical luminescence. 
1 mM D-luciferin in water. Store at -20°C in the 
dark. 
Luciferase enzyme stock solution: 2 mg/ml in 0.1 M 
sodium phosphate, pH 7.8. Store at -20°C in the dark. 
Luciferase buffer 1: 25 mM glycylglycine, pH 7.8, 15 
mM MgS04, 4 mM EGTA, 1 mM dithiothreitol, 1 mM 
PMSF (phenylmethanesulfonyl fluoride). 
Luciferase buffer 2: 0.27% Triton X-100,25 mM gly- 
cylglycine, pH 7.8, 15 mM MgSO,, 4 mM EGTA, 1 mM 
DTT, 15 mM KH2P04, 2 mM ATP. 
Luciferase buffer 3: 0.2 mM luciferin, 25 mM glycyl- 
glycine, pH 7.8, 15 mM MgS04, 4 mM EGTA, 2 mM 
dithiothreitol. 
PMSF: 100 mM reconstituted in 100% ethanol. Store 
at -20°C. 




Tissue homogenizer: Brinkmann. 
Centrifuge: Beckman J-21. 
68°C water bath. 
37°C water bath. 
Microcentrifuge: Eppendorf. 
Speedy-Vat: Savant. 
Thin-layer chromatography chamber. 
Betascope 603: Betagen. 
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Luciferase Assay 
Luminometer: Pharmacia Bio-Orbit 1251. 
METHODS 
Selection of Reporter Genes for Studies of Cardiac 
Transcriptional Regulation 
Several different reporter genes have been used for 
studies of transcriptional regulation following direct 
DNA injection into myocardium. These include P-ga- 
lactosidase, chloramphenicol acetyltransferase, and 
firefly luciferase. These genes were chosen because they 
are not expressed in cardiac myocytes in vivo and be- 
cause they can be easily assayed either in vivo or in 
uitro. Each gene offers unique advantages. P-Gal is a 
bacterial enzyme whose expression can be directly vi- 
sualized in standard histological specimens using a 
commercially available chromogenic substrate that 
causes cells expressing the enzyme to stain blue (6). 
Thus, histochemical staining for P-Gal can be used to 
determine the number and type of cells expressing re- 
combinant genes following direct DNA injection in 
vivo. However, P-Gal cannot be used to quantitate total 
levels of recombinant gene expression in DNA-injected 
hearts because the presence of even small amounts of 
blood in tissue homogenates interferes with the in vitro 
chromogenic P-Gal assay. In contrast to P-Gal, both 
CAT and luciferase can be used to accurately quantitate 
levels of reporter gene expression in total heart ho- 
mogenates. CAT is a bacterial enzyme that catalyzes 
an acetylation reaction that is easily assayed by thin- 
layer chromatography (7). In the presence of an ap- 
propriate substrate and ATP, luciferase generates light 
which can be quantitated using a luminometer (8). Al- 
though both assays are convenient, luciferase assays 
have the advantage of being more sensitive than CAT 
assays. Thus, luciferase reporter constructs are a better 
choice if low levels of expression are expected. Which- 
ever reporter plasmid is chosen, it is always necessary 
to include a reference plasmid in each DNA injection 
in order to correct for differences in transduction ef- 
ficiencies in different animals. We generally include 25 
pg of the pRSVCAT or pRSV-luciferase reference 
plasmids, respectively, in injections using luciferase and 
CAT reporter plasmids. 
Selection of Transcriptional Regulatory Sequences 
for Expressing Recombinant Genes in Cardiac 
Myocytes in vivo 
Several different viral and eukaryotic promoters have 
been used to program high-level gene expression in 
cardiac myocytes in viuo (2-5). These include the Rous 
sarcoma virus long terminal repeat (RSV LTR) (9, lo), 
the slow/cardiac troponin C promoter/enhancer (ll), 
and the a-myosin heavy chain promoter (12). This last 
promoter has the unique advantage of being thyroid 
hormone responsive both in vitro and in vivo (3, 12, 
13). Thus it could be used to modulate recombinant 
gene expression in vivo. 
Preparation of DNA for Cardiac Injections 
Closed circular plasmid DNA for direct intracardiac 
injection is prepared by standard alkaline lysis and 
CsCl gradient centrifugation (14). It is important to 
remove all ethidium bromide from the DNA by re- 
peated extraction with water-saturated 1-butanol. Fol- 
lowing butanol extraction, the DNA is dialyzed twice 
against 2-liter changes of 10 mM Tris (pH 7.8) for a 
total of 12 h at 4°C and ethanol precipitated. Thirty 
minutes prior to injection, the DNA is resuspended at 
a concentration of 1 mg/ml in sterile 10 mM NaH2P04, 
0.88% sodium chloride, pH 7.4. Because one report has 
shown that EDTA in the injection vehicle may be toxic 
to myocardial cells (4), EDTA is excluded from the 
DNA preparation and injection buffers. A total of 100- 
125 pg of DNA per animal is injected since studies in 
skeletal muscle have shown a linear dose response be- 
tween 10 and 100 pg of injected DNA (1). 
Surgical Procedure 
Both rats and mice can be used for intracardiac DNA 
injection. However, because of their larger size, rats 
are significantly easier to intubate and to inject with 
DNA. Most experiments have employed 6- to ll-week- 
old Sprague-Dawley rats, although animals as young 
as 4 weeks have been used successfully. Rats are anes- 
thetized with 200 mg/kg of avertin (freshly prepared 
as a 5% (v/v) solution in PBS) ip and ketamine (40 
mg/kg) im. Mechanical ventilation of the animal is 
essential to prevent a fatal pneumothorax following 
entry of the pleural cavity. Therefore, immediately fol- 
lowing anesthesia, animals are intubated using a O- 
sized Miller short laryngoscope, modified for rat surgery 
by cutting the blade in half lengthwise, and a long 18- 
or 20-gauge angiocatheter, modified so that its length 
approximates the distance between the animal’s mouth 
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and the tracheal bifurcation. The endotracheal tube is 
secured with a suture. Rats are mechanically ventilated 
using a small-animal respirator set at a tidal volume 
of 1.5 ml and a rate of 60 respirations/min. The anes- 
thetized animal is positioned on its right side. The left 
side of the chest is shaved and sterilized using a be- 
tadine solution. A skin incision is made parallel to the 
ribs half-way between the shoulder and the costal mar- 
gin. The superficial musculature is then dissected with 
fine scissors. This manipulation is usually accompanied 
by minor bleeding that can be stopped either by cautery 
or by pressure over the cut blood vessel. The fourth or 
fifth intercostal space is identified, and the intercostal 
muscles are cut with fine, blunt-tipped scissors. The 
actual incision should be made at midchest and just 
above the rib in order to avoid cutting intercostal ves- 
sels that course over the inferior margin of each rib. It 
is essential to enter the pleural cavity in a controlled 
manner. Sudden entrance of the chest, especially with 
sharp-tipped scissors, may puncture the underlying 
lung, invariably resulting in an inability to wean the 
animal from the ventilator at the end of the procedure. 
Once the chest wall has been opened, the intercostal 
incision is enlarged to allow the cross-action retractor 
to be inserted into the chest. This retractor should have 
blunt prongs to minimize the risk of inadvertent dam- 
age to the underlying lung. When the retractor has 
been opened, the lung is moved aside using cotton 
pledgets. The heart should be clearly visible (Fig. 1). 
The pericardium is dissected using fine forceps, and 
the cardiac apex is identified. This is the thickest por- 
tion of the heart and is therefore ideal for injection. 
One hundred microliters of DNA solution is then in- 
jected directly into the beating left ventricular apex 
using a tuberculin syringe and a 30-gauge needle. There 
should be no air in the hub of the syringe, and the bevel 
of the needle should be facing upward. A successful 
injection is accompanied by blanching and blebbing of 
the entire apical and anterior walls of the heart. There 
may be a few premature ventricular contractions during 
the injection, but we have not observed sustained ar- 
rhythmias. 
Following DNA injection the chest wall incision is 
closed in layers. The pleural cavity is closed using one 
or two interrupted nonresorbable sutures (silk or pro- 
lene) to appose the fourth and fifth ribs. Care must be 
taken not to puncture the lung with the suturing needle. 
Before the last suture is secured, a long 20-gauge an- 
giocatheter attached to a syringe is inserted into the 
pleural cavity. As the last suture is tightened, air is 
withdrawn from the pleural cavity to reduce the pro- 
cedure-related pneumothorax. The muscle layer is then 
closed with interrupted resorbable suture. Finally, the 
skin is closed with staples. The animals are extubated 
after a brief trial of breathing off of the ventilator with 
the endotracheal tube in place and are allowed to re- 
cover under a warming lamp. They are then placed in 
individual cages to prevent postoperative animals from 
opening and infecting each other’s surgical wounds. 
Tissue Harvest 
Cardiac myocytes 
combinant genes as 
injections, and gene 
express significant levels of re- 
early as 48 h after direct DNA 
expression remains stable for at 
least 6 months (2, 3,5). Thus, the timing of tissue har- 
vest depends entirely on the experiment being per- 
formed. In general, for studies of transcriptional reg- 
ulation in the heart using CAT or luciferase reporter 
plasmid, hearts are harvested 5 days following DNA 
injection. To remove an injected heart, the animal is 
euthanized using pentobarbital (100 mg/kg, ip). A 
midline sternotomy is performed using coarse dissect- 
ing scissors. The heart is quickly removed from the 
chest and rinsed extensively in ice-cold Dulbecco’s PBS 
to remove any residual blood from the ventricle. As 
FIG. 1. View of the operative field during DNA injection into 
myocardium. DNA is injected into the apical portion of the left ven- 
tricle using a 30-gauge needle and tuberculin syringe. 
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described in detail below, hearts are prepared differ- 
ently depending on the assay to be performed. 
P-Gal Assay 
As described above, the P-Gal assay can be used to 
histologically visualize myocardial cells that take up 
and express @-Gal expression vectors following direct 
DNA injection in. uiuo. The glutaraldehyde, ferro/fer- 
ricyanide, and X-Gal staining solutions (see Materials 
and Reagents) are prepared immediately prior to har- 
vesting of the heart. Following harvest, the heart is cut 
into 3- to &mm-thick sections using a scalpel or razor 
blade and fixed in the glutaraldehyde solution for 10 
min at room temperature. The heart sections are rinsed 
extensively in calcium-free PBS (P-Gal is inhibited by 
calcium). The sections are then placed directly into the 
X-Gal staining solution and incubated at 37°C in the 
dark overnight. The following morning, the heart slices 
are rinsed extensively in PBS, dehydrated with ethanol, 
and embedded in glycol methacrylate. The tissue is 
then sectioned at 4-pm thickness using standard tech- 
niques. The sections are counterstained with hema- 
toxylin and eosin to visualize the cardiac architecture. 
CAT Assay 
Chloramphenicol acetyltransferase catalyzes the 
acetylation of 14C-labeled chloramphenicol in the pres- 
ence of acetyl-CoA. The radiolabeled chloramphenicol 
and its acetylated analogues can be separated using 
thin-layer chromatography and quantitated using ei- 
ther a betascope or liquid scintillography. The ratio of 
acetylated to unacetylated chloramphenicol is directly 
proportional to the level of CAT enzyme expressed in 
the heart. 
Following harvest and washing, the atria are removed 
and discarded. The ventricles are then placed in 1 ml 
of ice-cold homogenization solution (0.25 M Tris-HCl, 
pH 7.8) if the tissue is to be assayed only for CAT 
activity or luciferase buffer 1 if both CAT and luciferase 
activities are to be measured. The tissue is homogenized 
on ice three times for 45 s each. The homogenate is 
allowed to cool on ice for 2 min between each homog- 
enization step. The crude homogenate is centrifuged 
for 10 min in a Beckman 517 rotor at 6750g. Two mi- 
croliters of the supernatant is assayed for protein con- 
tent using a commercially available kit (Bio-Rad) and 
the remainder is stored at -70°C until it is assayed for 
CAT activity. For CAT assays approximately 3 mg of 
total protein is diluted into 100 ~1 of either 0.25 M Tris- 
HCl, pH 7.8, or luciferase buffer 1 and heated to 68°C 
for 10 min to denature endogenous acetyltransferases. 
The sample is centrifuged at 14,000 rpm in a micro- 
centrifuge (Eppendorf) at room temperature and the 
pellet is discarded. The volume of the supernatant is 
readjusted to 100 ~1 with the appropriate homogeni- 
zation buffer. 
For CAT assays the loo-p1 samples are mixed with 
19 ~1 of 2 M Tris-HCl, pH 7.4, 20 ~1 of 4 mM acetyl- 
CoA, and 8 yl of [14C]chloramphenicol. The mixture is 
incubated for 2 h at 37°C. The chloramphenicol and 
its acetylated analogues are then extracted with ethyl 
acetate and separated by thin-layer chromatography 
according to standard procedures (7). Radioactivity in 
the spots corresponding to unacetylated and acetylated 
chloramphenicol is quantitated either on a betascope 
or by liquid scintillography. 
Luciferase Assay 
Fresh luciferase buffers 1, 2, and 3 (see Materials 
and Reagents) and standard dilutions (1:104, 1:105, 
1:106, 1:107, and 1:lO’) of the luciferase stock solution 
(2 mg/ml or 3 X lOlo LU/ml in luciferase buffer 1) in 
luciferase buffer 1 are prepared immediately prior to 
the assay. All reagents are stored on ice until all the 
samples are ready to be tested. Immediately prior to 
the assay, 10 ~1 of each luciferase standard solution 
plus 90 ~1 of luciferase buffer 2 or 100 ~1 of cardiac 
homogenate is added to 350 ~1 of luciferase buffer 2 in 
a luminometer cuvette. The samples are then allowed 
to equilibrate to room temperature. 
Samples are placed in the luminometer and assayed 
in series after the mechanical addition of 100 ~1 of lu- 
ciferase buffer 3. Luciferase concentrations are read 
from a standard curve prepared by plotting the log lu- 
ciferase concentration vs the log light units. For studies 
of transcriptional regulation using CAT reporter con- 
structs and luciferase reference plasmids, CAT activ- 
ities are corrected for differences in transduction effi- 
ciencies using the luciferase reference values from the 
same cardiac homogenates. 
RESULTS AND DISCUSSION 
Patterns and Mechanisms of DNA Uptake and 
Expression Following Direct DNA Injection in 
Myocardium in vivo 
The efficiency, stability, and cell specificity of re- 
combinant gene expression in the heart have been 
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evaluated following the injection of several different /3- 
Gal and CAT reporter plasmids. The results can be 
summarized as followed: (i) Recombinant genes are 
expressed in a small percentage (~1%) of cardiac myo- 
cytes following direct DNA injection (Fig. 2) (2,5). (ii) 
Expression is observed only in cardiac myocytes and 
is never detected in fibroblasts or vascular cells within 
the heart (2, 5). (iii) Recombinant gene expression is 
observed as early as 48 h after injection (2-5). Three 
reports have demonstrated stable expression of injected 
plasmids for periods of as long as 6 months (2, 3, 5). 
In contrast, one study reported an immune-mediated 
extinction of recombinant gene expression within 28 
days following injection (4). Whether this discrepancy 
reflects differences in injection technique, recipient 
animals, or DNA preparation remains unclear. (iv) A 
mild to moderate localized inflammatory response at 
the injection site has been noted within the first 5 days 
following injection (Fig. 2) (2,5). By 1 to 6 months this 
response resolved into an area of mild local fibrosis (2, 
5). Changes in the preparation of DNA and the injec- 
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tion solution may minimize this inflammatory re- 
sponse. 
The mechanism of DNA uptake and expression by 
cardiac myocytes following direct DNA injection re- 
mains unclear. The ability to take up and express in- 
jected plasmid DNA is unique to muscle and may 
therefore reflect unique transport pathways or bio- 
physical characteristics of the muscle cell lineage. An 
important question concerns the physical state of plas- 
mid DNA following uptake into cardiac myocytes in 
uiuo. Using Southern blot analysis, Acsadi et al. (4) 
have reported that the majority of the injected plasmid 
DNA is maintained in cardiac myocytes as linear or 
closed circular plasmid and does not appear to integrate 
into the genome or to undergo DNA replication. This 
finding is important because it suggests that the risk 
of mutagenesis from random integration of injected 
DNA is minimal. Current efforts are focused on in- 
creasing the efficiency of DNA uptake and expression 
in order to adapt the technique for the treatment of 
cardiovascular diseases. 
FIG. 2. Expression of recombinant P-Gal in cardiac myocytes following the direct injection of pRSV@-gal DNA into the left ventricular 
wall of Sprague-Dawley rats. Hearts were harvested, fixed in glutaraldehyde, and stained with X-Gal as described under Methods. (A) 18X 
view of a 3-mm heart section. (B and C) 125X and 250X views, respectively, of 4-pm sections from a heart 3 days after pRSV@-gal injection. 
P-Gal activity is seen only within cardiac myocytes, which can be distinguished by their myofibrillar architecture. 
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Mapping Transcriptional Regulatory Sequences Using 
Direct DNA injection into Myocardium 
We have used the direct injection of CAT reporter 
plasmids into myocardium to map the transcriptional 
regulatory sequences of the slow/cardiac troponin C 
(cTnC) gene in uivo (11). A series of deletion constructs 
containing sequences from the 5’ flanking region of the 
murine cTnC gene along with the pRSV-luciferase ref- 
erence plasmid were injected into the left ventricular 
walls of adult Sprague-Dawley rats. Five days later, 
the animals were sacrificed, and cardiac homogenates 
were assayed for CAT and luciferase activities. CAT 
activities were normalized for differences in transfec- 
tion efficiencies by assaying the same cardiac homog- 
enates for luciferase activities. Consistent with results 
obtained using in vitro transfections of neonatal rat 
cardiomyocytes, a reporter construct containing 156 
bp of the cTnC gene 5’ flanking region (bp -124 to 
+32) reproducibly increased CAT transcription by 
more than 6%fold following injection into the rat ven- 
tricle (Fig. 3). Further analysis of this element by direct 
injection of CAT reporter constructs demonstrated that 
it is composed of a minimal proximal promoter (bp 
-79 to +32) and a cardiac-specific transcriptional en- 
hancer (bp -124 to -56) (11) (Fig. 3). These results 
were reproducibly obtained in multiple animals. 
Direct DNA injection has also been used to examine 
the effects of hormonal manipulation on cardiac tran- 
scriptional regulation. Kitsis et al. (3) injected a lucif- 
erase reference gene coupled to the ol-myosin heavy 
chain promoter, a thyroid hormone-responsive, car- 
diac-specific regulatory element (12, 13), along with 
the pRSVCAT reference plasmid into the ventricular 
walls of euthyroid, hypothyroid, and hyperthyroid rats. 
Luciferase activities were normalized for differences in 
transfection efficiencies by assaying cardiac homoge- 
nates for CAT activity. Hypothyroid animals treated 
with triiodothyronine (T3), a naturally occurring thy- 
roid hormone, displayed significantly increased lucif- 
erase activity compared with untreated hypothyroid 
rats or euthyroid controls. The increase in activity was 
also seen in animals rendered hyperthyroid by injection 
of T3 compared to euthyroid control animals. Thus, 
genes introduced into cardiac myocytes by DNA injec- 
tion can be hormonally modulated. Taken together, 
the results obtained in the cTnC and a-MHC systems 
demonstrate the usefulness of direct DNA injection 
for studies of cardiac-specific transcriptional regula- 
tion. 
Direct DNA Injection for Somatic Gene Therapy in the 
Heart 
The ability to stably express recombinant genes in 
the heart holds promise for the treatment of a variety 
of acquired and inherited cardiac diseases. These in- 
clude inherited cardiomyopathies such as that asso- 
ciated with Duchenne muscular dystrophy and acquired 
cardiomyopathies such as that associated with chronic 
Relative CAT 
Activity 
FIG. 3. In viuo analysis of the c&-acting sequences that regulate the expression of the cardiac troponin C (cTnC) gene. 100 pg of cTnC/ 
CAT reporter constructs (shown schematically on the left), along with 25 kg of the pRSV-luciferase reference plasmid, was injected directly 
into the left ventricular wall of Sprague-Dawley rats. Five days later, the animals were sacrificed and cardiac homogenates assayed for 
CAT and luciferase activities as described under Methods. A representative CAT assay is shown on the right. The data are presented as 
CAT activity following correction for differences in transduction efficiencies. 
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ischemic heart disease. Effective gene replacement 
therapy for inherited cardiomyopathies will require 
significant improvements in the efficiency of recom- 
binant gene uptake and expression. In contrast, it may 
be possible to stimulate collateral circulation in areas 
of ischemic myocardium by injecting expression vectors 
encoding secreted forms of mammalian angiogenesis 
factors into the myocardium. Toward this end we are 
currently injecting 4-week-old Sprague-Dawley rats 
with expression vectors encoding human fibroblast 
growth factor-5, a secreted and potent angiogenesis 
factor not normally expressed in myocardium. 
CONCLUSION 
We have described a method for in vivo transfer of 
recombinant genes into cardiac myocytes by direct in- 
jection of purified plasmid DNA into the beating left 
ventricular wall. This approach represents a novel and 
economical method for studying transcriptional regu- 
lation in cardiac myocytes in vivo. In addition, it holds 
promise as a potential method of somatic gene therapy 
in the heart. 
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